**Supplementary Table 2.** Prescription status of quadruple combination of OHAs in study population at baseline

| Quadruple combinations (n=357) | No. (%) |
|-------------------------------|---------|
| Metformin Sulfonylurea or glinide DPP4 inhibitor Thiazolidinedione | 226 (63.3) |
|                              | SGLT2 inhibitor  | 67 (18.8) |
|                              | α-Glucosidase inhibitor | 15 (4.2) |
| Thiazolidinedione SGLT2 inhibitor | 12 (3.4) |
| Thiazolidinedione α-Glucosidase inhibitor | 7 (2.0) |
| α-Glucosidase inhibitor SGLT2 inhibitor | 6 (1.7) |
| DPP4 inhibitor Thiazolidinedione SGLT2 inhibitor | 20 (5.6) |
| Sulfonylurea or glinide Thiazolidinedione DPP4 inhibitor SGLT2 inhibitor | 2 (0.5) |
|                              | α-Glucosidase inhibitor | 2 (0.5) |

OHA, oral hypoglycemic agent; DPP4, dipeptidyl peptidase 4; SGLT2, sodium-glucose cotransporter 2.